Another unimolecular once-weekly dual GLP-1R/GCGR agonist is efinopegdutide (MK-6024), which was able to prove significant reductions in body weight compared to placebo, but no reductions of the HbA1c levels, when investigated in people with obesity and T2DM. Here, GLP1R is linked to type 2 diabetes mellitus.